Vilazodone 20mg Tablets

Vilazodone 20 mg Tablets – Generic Viibryd

Vilazodone 20 mg Tablets are a generic form of Viibryd, containing vilazodone hydrochloride as the active ingredient. Vilazodone is an oral antidepressant used to treat major depressive disorder (MDD) in adults where approved. Major depressive disorder is a mental health condition that can affect mood, interest in activities, sleep, appetite, concentration and everyday functioning.

Vilazodone belongs to a pharmacological class that combines serotonin reuptake inhibition with partial agonist activity at 5-HT1A serotonin receptors. These actions affect serotonergic neurotransmission, which is involved in mood regulation.

The 20 mg tablet is used within a prescribed treatment regimen. The appropriate dose, treatment schedule and monitoring plan depend on the patient's clinical circumstances and the prescribing information applicable in the relevant country.

Product Information

Important Assessments Before Treatment

Before vilazodone treatment begins, the prescriber should review the patient's medical history, current medicines and relevant risk factors. Assessments may include:

• Mental health assessment: Review depressive symptoms, previous treatment, suicidal thoughts and behavioral changes.
• Bipolar disorder screening: Assess personal and family history of bipolar disorder, mania or hypomania.
• Medication review: Identify serotonergic medicines, anticoagulants and other potential interacting drugs.
• Bleeding risk: Consider medical history and medicines that can increase bleeding.
• Seizure history: Assess relevant seizure disorders or risk factors.
• Pregnancy considerations: Discuss pregnancy, plans for pregnancy and breastfeeding where applicable.
• Follow-up plan: Arrange monitoring for clinical response, adverse effects and changes in symptoms.

The extent of monitoring depends on individual circumstances and the applicable product information.

Generic Viibryd vs. Brand Viibryd

Viibryd is the reference brand containing vilazodone. Generic vilazodone tablets contain the same active ingredient and corresponding strength when authorized as a generic equivalent.

The generic product may differ from the reference brand in manufacturer, tablet appearance, packaging and inactive ingredients. The actual product label identifies the manufacturer, formulation, pack size and applicable market authorization.

Vilazodone Compared With Other Antidepressants

Vilazodone is one of several medicines used to treat depression. Other antidepressants include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs) and other medicines with different pharmacological mechanisms.

These treatments are not automatically interchangeable. Choice of treatment depends on the diagnosis, symptoms, previous treatment response, other medical conditions, potential interactions, adverse-effect profiles and prescribing guidance.

How it works

Vilazodone inhibits the serotonin transporter, reducing serotonin reuptake, and acts as a partial agonist at 5-HT1A serotonin receptors. These actions influence serotonergic signalling in the central nervous system.

The exact contribution of each pharmacological action to vilazodone's antidepressant effect is not fully established. Its clinical effect develops over time, and response varies between individuals.

Vilazodone is a treatment for depression rather than a cure. Treatment planning and monitoring should be guided by a qualified healthcare professional.

Vilazodone is used to treat adults with major depressive disorder under the US prescribing information. The exact approved indication, age requirements and product availability depend on national authorization and the specific product label.

1. Major Depressive Disorder

Major depressive disorder can involve persistent low mood, loss of interest or pleasure, changes in sleep or appetite, reduced energy, difficulty concentrating and changes in everyday functioning. Vilazodone is a prescription treatment option for eligible adults following clinical assessment.

2. Adult Depression Treatment

Treatment decisions take account of symptom severity, previous treatment response, medical history, other medicines and individual safety considerations. Vilazodone is not an immediate-relief medicine, and improvement may take several weeks.

3. Ongoing Symptom Management

A prescriber may review response and tolerability during treatment and adjust the regimen when appropriate. Continued follow-up is important to evaluate clinical benefit, adverse effects and the need for ongoing treatment.

The appropriate dose depends on the prescription, patient characteristics, tolerability and the locally approved product information.

Under US prescribing information for adults with major depressive disorder, treatment starts at 10 mg orally once daily with food for seven days, followed by 20 mg once daily with food. Depending on response and tolerability, the dose may be increased to 40 mg once daily after at least seven days between dose increases.

Vilazodone should be taken with food because food affects its absorption.

Administration Instructions

• Take the tablet with food and follow the prescribed schedule.
• Follow the clinician's instructions for starting treatment and any dose increases.
• Do not increase or reduce the dose independently.
• If a dose is missed, follow the product leaflet or ask a pharmacist for guidance. Do not take a double dose to compensate.
• Do not discontinue treatment abruptly without medical advice; gradual dose reduction may be needed.
• Consult the prescriber before restarting after a significant treatment interruption.

The regimen above reflects US prescribing information and is not an individualized prescription. Follow the current local product label and the treating healthcare professional's directions.

Vilazodone can cause side effects, and their severity varies between patients. Reported adverse effects include:

• Diarrhea
• Nausea
• Vomiting
• Insomnia
• Dizziness
• Other gastrointestinal symptoms

Important less common or serious risks include serotonin syndrome, increased bleeding, mania or hypomania, seizures, hyponatremia and discontinuation symptoms.

Seek urgent medical attention for suspected serotonin syndrome, a seizure, a severe allergic reaction or an immediate risk of self-harm. Contact the prescriber about persistent or troublesome adverse effects.

Suicidal Thoughts and Behavioral Changes

Antidepressants carry a warning about an increased risk of suicidal thoughts and behaviors in children, adolescents and young adults. Monitor for worsening depression, unusual behavioral changes, severe agitation or emerging suicidal thoughts, particularly when treatment starts or the dose changes. Imminent danger requires emergency assistance.

Serotonin Syndrome

Vilazodone can cause serotonin syndrome, particularly when combined with other serotonergic medicines. Warning symptoms may include agitation, confusion, sweating, fever, rapid heartbeat, tremor, muscle rigidity or impaired coordination. Suspected serotonin syndrome requires urgent medical assessment.

Bleeding Risk

Vilazodone may increase bleeding risk, particularly when taken with aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), antiplatelet medicines or anticoagulants. Inform the prescriber about all medicines and supplements.

Bipolar Disorder and Mania

Patients should be assessed for a personal or family history of bipolar disorder before starting treatment. Antidepressants may trigger mania or hypomania in susceptible individuals.

Seizures

Patients with a seizure disorder or factors that increase seizure risk require clinical assessment before treatment. Report any seizure history to the prescriber.

Low Sodium Levels

Antidepressants can be associated with hyponatremia, or low blood sodium. Older adults, people taking diuretics and individuals who are volume-depleted may have an increased risk. New confusion, severe weakness, marked unsteadiness or severe headache should be medically assessed.

Pregnancy and Breastfeeding

Discuss pregnancy, plans for pregnancy and breastfeeding with the prescriber before starting or changing treatment. The decision should consider the potential benefits of treatment, the risks of untreated depression and the available evidence. Do not stop vilazodone without professional advice.

Discontinuation

Stopping vilazodone abruptly may cause discontinuation symptoms. If treatment is to be stopped, the prescriber may recommend a gradual dose reduction and follow-up.

Contraindications and Drug Interactions

Under US prescribing information, vilazodone is contraindicated with monoamine oxidase inhibitors (MAOIs) and during the specified period after MAOI treatment because of the risk of serotonin syndrome.

Potential interactions include:

• Other serotonergic medicines, including certain antidepressants, triptans, tramadol and lithium.
• Aspirin, NSAIDs, antiplatelet medicines and anticoagulants, which may increase bleeding risk.
• Strong CYP3A4 inhibitors, which can increase vilazodone exposure and may require dose adjustment.
• Strong CYP3A4 inducers, which can reduce vilazodone exposure and affect treatment response.
• Other medicines or substances that may increase adverse effects or impair alertness.

The precise contraindications, washout periods and interaction instructions should be checked against the current product label and the patient's medication list.